Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Breast Cancer

In the cancer care setting, telehealth was perceived favorably by patients and providers, providing a new pathway for accessing treatment in the future.
The pandemic shifted patients’ fears, highlighting the critical importance of physician trust and language used in recruitment.
The delivery of care transformed rapidly as healthcare systems innovated to handle the COVID-19 pandemic. The overarching goals and principles of cancer care did not change, but there was a heightened recognition of the challenges faced by cancer patients.
The latest quality-of-life research from the MONALEESA-7 trial supports a strong clinical benefit-to-risk ratio with ribociclib-based treatment in pre- and perimenopausal patients.
In the future, telehealth may help overcome obstacles to healthcare access for underserved populations.
We have taken part in a unique evolution in medicine, as we have modified our clinical processes and practices, clinical trials and research programs, and educational vehicles because of the COVID-19 pandemic in 2020.
Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.
In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.
Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative, endocrine-sensitive, advanced breast cancer.
Page 4 of 21
Results 31 - 40 of 209